.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
QuintilesIMS
Cerilliant
Dow
McKesson
Moodys
Teva
Daiichi Sankyo
Fish and Richardson
AstraZeneca

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 201444

« Back to Dashboard

NDA 201444 describes NITHIODOTE, which is a drug marketed by Hope Pharms and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the NITHIODOTE profile page.

The generic ingredient in NITHIODOTE is sodium nitrite; sodium thiosulfate. There are one thousand four hundred drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sodium nitrite; sodium thiosulfate profile page.

Summary for 201444

Tradename:1
Applicant:1
Ingredient:1
Patents:4
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 201444

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NITHIODOTE sodium nitrite; sodium thiosulfate SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS 201444 NDA Hope Pharmaceuticals 60267-812 60267-812-00 1 KIT in 1 CARTON (60267-812-00) * 10 mL in 1 VIAL, SINGLE-USE (60267-311-10) * 50 mL in 1 VIAL, SINGLE-USE (60267-705-50)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUSStrength300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML)
Approval Date:Jan 14, 2011TE:RLD:Yes
Regulatory Exclusivity Expiration:Jan 14, 2018
Regulatory Exclusivity Use:ORPHAN DRUG EXCLUSIVITY
Patent:► SubscribePatent Expiration:Mar 29, 2031Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING
Patent:► SubscribePatent Expiration:Dec 24, 2031Product Flag?YSubstance Flag?YDelist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Deloitte
Medtronic
Novartis
Boehringer Ingelheim
AstraZeneca
Citi
Teva
Express Scripts
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot